← All trials
NCT04663555
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 1, 2021
- Primary completion
- Mar 31, 2022
- Completion date
- Mar 31, 2023
- First posted
- Dec 11, 2020
- Last posted
- Dec 11, 2020
- Enrollment
- 300
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University Hospital BrnoLead sponsor
- Charles UniversityCollaborator
- University Hospital BrnoReponsible party - principal investigator
- University of OstravaCollaborator
- Palacky UniversityCollaborator
- Masaryk UniversityCollaborator
- Teaching Hospital Královské Vinohrady (FNKV)Collaborator
- Teaching Hospital Královské Vinohrady (FNKV)Collaborator
- Charles UniversityCollaborator
- University Hospital PlzeňCollaborator
- Charles UniversityCollaborator
- Tomáš Baťa Regional HospitalCollaborator
- Government of Czech RepublicCollaborator
- University Hospital BrnoCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.